GlaxoSmithKline Plc the maker of the diabetes drug  Avandia has agreed to pay 3 billion dollars to resolve their U.S. criminal and civil investigations into whether the company marketed the drug for unapproved uses. The potential settlement puts the company closer to settling the legal probes into its practices.

The investigation in Glaxo began in 2004 in Colorado when federal prosecutors began to investigate whether Glaxo promoted drugs for unapproved uses and into ways the company potentially influenced doctors.